Incorporation of PDX-based In Vitro Assays into Preclinical Oncology Programs


Cancer is a very complex disease that requires investigation from many different viewpoints and leverages a variety of research tools. One such tool is our collection of more than 70 proprietary tumor cell lines established from patient-derived xenograft (PDX) material. This webinar focuses on the quick and cost-effective data generation using in vitro cell-based assays with well-characterized tumor cell lines and tumor xenografts, including examples for biomarker analysis via bioinformatics approaches. These examples may serve as tools to select appropriate models and/or conditions for in vivo follow-up studies with the potential to boost preclinical oncology research.

Presenter

  • Armin Maier, PhD Lab Head, Cell Biology & Compound Screening Charles River, Freiburg, Germany